Evidence map›Paper›PMID 28706038›Full record

ReviewScience (New York, N.Y.)2017

Improving vaccine trials in infectious disease emergencies.

Marc Lipsitch, Nir Eyal

Abstract readReview
In one paragraph

Review in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Materials-based vaccines for infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  4. Article
  5. Article
  6. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marc LipsitchCenter for Communicable Disease Dynamics, Department of Epidemiology, and Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA. mlipsitc@hsph.harvard.edu.ORCID 0000-0003-1504-9213
Nir EyalDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0003-1056-6609

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI HANAGE, WILLIAM · 2009 to 2018
$26.4M
NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

Unprecedented global effort is under way to facilitate the testing of countermeasures in infectious disease emergencies. Better understanding of the various options for trial design is needed in advance of outbreaks, as is preliminary global agreement on the most suitable designs for the various scenarios. What would enhance the speed, validity, and ethics of clinical studies of such countermeasures? Focusing on studies of vaccine efficacy and effectiveness in emergencies, we highlight three needs: for formal randomized trials-even in most emergencies; for individually randomized trials-even in many emergencies; and for six areas of innovation in trial methodology. These needs should inform current updates of protocols and roadmaps.

Indexed as

Immunogenicity, VaccineCommunicable Diseases, EmergingDisease OutbreaksHumansRandomized Controlled Trials as TopicResearch DesignVaccinesVaccines

Identifiers

PMID28706038
PMCPMC5568786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.